CD274 and hepatocellular carcinoma: In an IMBrave150 trial, the combination of bevacizumab (anti-VEGF-A antibody) and atezolizumab (anti-PD-L1 antibody) showed better OS than sorafenib, the standard of care for first-line systemic therapy in metastatic HCC [10].